Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference

Cambridge, Massachusetts, UNITED STATES

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit

Matt Lane

Tom Donovan